Warning! GuruFocus has detected 3 Severe warning signs with CANF. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Can Fite Biofarma Ltd () from 2012 to Apr 13 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Can Fite Biofarma stock (CANF) PE ratio as of Apr 13 2021 is 0. More Details
Can Fite Biofarma PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Can Fite Biofarma PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is a clinical-stage biopharmaceutical company. The company is focused on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune inflammatory indications, oncology and liver diseases as well as sexual dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. The company's pipeline drugs are synthetic, specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile.